Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/newlimit.md — the filesystem corpus, unchanged. Not an edit.
10.1 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["reprogramming", "transcription factors", "epigenetics", "biotech", "aging", "liver"]tags: ["reprogramming", "transcription factors", "epigenetics", "biotech", "aging", "liver"]summary: "A biotechnology company founded in 2021 to screen transcription-factor combinations that restore youthful function to aged cells without changing their identity."summary: "A biotechnology company founded in 2021 to screen transcription-factor combinations that restore youthful function to aged cells without changing their identity."updated: "2026-07-27"updated: "2026-10-29"issues: ["The 2024 public data release and the 2025 funding round are described without a source."]issues: ["The 2024 public data release and the 2025 funding round are described without a source."]------ lines 30–38 → 30–3816 unchanged lines not shown
## Overview## Overview The company's technical bet is that the canonical [[yamanaka-factors]] are a poor tool for rejuvenation. The four-factor set was selected by Takahashi and Yamanaka for its ability to drive cells all the way to pluripotency,[^takahashi2006] which is precisely the property that makes it dangerous in a living animal — cells that lose identity form teratomas. NewLimit's premise is that the space of transcription factors contains combinations that produce the rejuvenation without the dedifferentiation, and that finding them is a search problem rather than a mechanism problem.The company's technical bet is that the canonical [[yamanaka-factors]] are a poor tool for rejuvenation. Takahashi and Yamanaka selected the four-factor set for its ability to drive cells all the way to pluripotency,[^takahashi2006] which is precisely the property that makes it dangerous in a living animal, where cells that lose identity form teratomas. NewLimit's premise is that the space of transcription factors contains combinations that produce the rejuvenation without the dedifferentiation, and that finding them is a search problem rather than a mechanism problem. That framing determines the company's structure. Most of its investment is in the screening platform: delivering combinatorial sets of factors into primary human cells, measuring the result with single-cell transcriptomics and functional assays, and using the data to select the next round.That framing shapes the company. Most of its investment goes into the screening platform: delivering combinatorial sets of factors into primary human cells, measuring the result with single-cell transcriptomics and functional assays, and using the data to select the next round. ## History## History lines 43–49 → 43–494 unchanged lines not shown
```timeline```timeline[[ { "year": "2021", "title": "Founded", "text": "Brian Armstrong and Blake Byers commit $105 million to a company built around transcription-factor screening, with Jacob Kimmel leading research." }, { "year": "2021", "title": "Founded", "text": "Brian Armstrong and Blake Byers commit $105 million to a company built around transcription-factor screening, with Jacob Kimmel leading research." }, { "year": "2022–2024", "title": "Platform build", "text": "The company focuses on combinatorial delivery, single-cell readouts and functional assays in primary human hepatocytes and T cells rather than on a named indication." }, { "year": "2022-2024", "title": "Platform build", "text": "The company focuses on combinatorial delivery, single-cell readouts and functional assays in primary human hepatocytes and T cells rather than on a named indication." }, { "year": "2024", "title": "Public data release", "text": "NewLimit publishes screening results and methodology openly, an unusual posture for a private longevity company." }, { "year": "2024", "title": "Public data release", "text": "NewLimit publishes screening results and methodology openly, an unusual posture for a private longevity company." }, { "year": "2025", "title": "Further funding", "text": "A venture round reported at roughly $130 million extends the platform and moves the company toward candidate selection." } { "year": "2025", "title": "Further funding", "text": "A venture round reported at roughly $130 million extends the platform and moves the company toward candidate selection." }]]lines 53–78 → 53–783 unchanged lines not shown
### The screening approach### The screening approach Reprogramming in its original form uses four factors delivered together and continuously. NewLimit instead treats the identity of the factors, their combination, their dose and their duration as variables to be optimized against a functional readout. The combinatorial space is enormous — the human genome encodes well over a thousand transcription factors — so the practical question is how to sample it efficiently, which is where machine-learning models trained on the company's own screening data are applied. It is the search logic of [[ai-drug-discovery]] pointed at factor combinations rather than at small molecules.Reprogramming in its original form uses four factors delivered together and continuously. NewLimit instead treats the identity of the factors, their combination, their dose and their duration as variables to be optimized against a functional readout. The combinatorial space is enormous, since the human genome encodes well over a thousand transcription factors. The practical question is how to sample it efficiently, and the company applies machine-learning models trained on its own screening data to that problem. This is the search logic of [[ai-drug-discovery]] pointed at factor combinations rather than at small molecules. The readouts matter as much as the search. A shift in an [[epigenetic-clock]] reading is cheap to measure and weakly informative; the company has emphasized functional assays instead, on the reasoning that a cell that looks younger by methylation but does not perform better is not a therapeutic result. This is the same measurement problem that constrains all claims about [[biological-age]].The readouts matter as much as the search. A shift in an [[epigenetic-clock]] reading is cheap to measure and weakly informative. The company has emphasized functional assays instead, reasoning that a cell that looks younger by methylation but does not perform better is not a therapeutic result. The same measurement problem constrains all claims about [[biological-age]]. ### Hepatocytes### Hepatocytes The company's lead cell type is the hepatocyte. The choice is pragmatic rather than sentimental: liver function declines measurably with age, primary human hepatocytes can be obtained and cultured, the liver is the tissue most readily reached by [[lipid-nanoparticles]] and by [[aav-vectors]], and there are age-associated liver conditions with recognized clinical endpoints. A rejuvenation therapy that only ever worked in the liver would still be a drug.The company's lead cell type is the hepatocyte, a pragmatic choice. Liver function declines measurably with age, primary human hepatocytes can be obtained and cultured, the liver is the tissue most readily reached by [[lipid-nanoparticles]] and by [[aav-vectors]], and there are age-associated liver conditions with recognized clinical endpoints. A rejuvenation therapy that only ever worked in the liver would still be a drug. ### Immune cells### Immune cells A second programme targets T cells, on the reasoning that immune decline with age — thymic involution, accumulation of exhausted and senescent lymphocytes, and the [[inflammaging|chronic inflammation]] that accompanies them — drives a large share of age-related mortality through infection and cancer. Chronic inflammation was added as a distinct hallmark of aging in the 2023 revision of that framework, which reflects how central immune dysfunction has become to the field's account of aging.[^lopez2023] Restoring T-cell function is also one of the three functional domains that the [[xprize-healthspan]] competition scores.A second programme targets T cells. Its reasoning is that immune decline with age drives a large share of age-related mortality through infection and cancer; that decline includes thymic involution, the accumulation of exhausted and senescent lymphocytes, and the [[inflammaging|chronic inflammation]] that accompanies them. The 2023 revision of the hallmarks framework added chronic inflammation as a distinct hallmark of aging, a sign of how central immune dysfunction has become to the field's account of aging.[^lopez2023] Restoring T-cell function is also one of the three functional domains that the [[xprize-healthspan]] competition scores. > [!key] Why identity is the constraint> [!key] Why identity is the constraint> The therapeutic target is a cell that is old but still the right kind of cell. Push reprogramming too far and a hepatocyte stops being a hepatocyte; push it too little and nothing changes. There is no theory that predicts where that boundary lies for a given factor set, which is why the field has resorted to empirical screening at scale.> The therapeutic target is a cell that is old but still the right kind of cell. Push reprogramming too far and a hepatocyte stops being a hepatocyte; push it too little and nothing changes. No theory predicts where that boundary lies for a given factor set, so the field has resorted to empirical screening at scale. ## Funding and posture## Funding and posture NewLimit is funded by its founders and by venture investors rather than by philanthropy, and its capital is roughly a tenth of what Altos Labs raised. The company has been explicit that this is a deliberate constraint: a smaller budget forces earlier decisions about what to measure.NewLimit is funded by its founders and by venture investors rather than by philanthropy, and its capital is roughly a tenth of what Altos Labs raised. The company has said explicitly that this is a deliberate constraint, because a smaller budget forces earlier decisions about what to measure. Its more distinctive choice is disclosure. NewLimit has published data releases and technical write-ups, including results that did not work, at a stage when most private biotechnology companies publish nothing. The stated rationale is that the field's central questions are pre-competitive and that public data attracts collaborators and scientific staff. The commercial cost of the policy is real, and whether it survives contact with a clinical programme is untested.Its more unusual choice is disclosure. NewLimit has published data releases and technical write-ups, including results that did not work, at a stage when most private biotechnology companies publish nothing. The stated rationale is that the field's central questions are pre-competitive and that public data attracts collaborators and scientific staff. The policy has a real commercial cost, and whether it will survive a clinical programme is untested. ## Reception## Reception lines 84–92 → 84–925 unchanged lines not shown
## Outlook## Outlook The decisions that will reveal whether the approach works are near. Does NewLimit name a factor set and an indication? Does it show rejuvenation of a functional parameter — regenerative capacity, metabolic output, drug clearance — in aged primary human cells and then in a large animal? Does it publish, as it has said it will, the results that fail?The decisions that will reveal whether the approach works are near. They are whether NewLimit names a factor set and an indication; whether it shows rejuvenation of a functional parameter, such as regenerative capacity, metabolic output, or drug clearance, in aged primary human cells and then in a large animal; and whether it publishes, as it has said it will, the results that fail. If the search succeeds, the outcome is likely to be modest and specific: a defined combination that improves one cell type's function, delivered locally, for one age-associated disease. That is a smaller claim than [[epigenetic-reprogramming]] rhetoric usually makes, and it is the version most likely to reach a patient. Whether such a therapy would generalize to the organism, which is what the [[geroscience-hypothesis]] requires, is a separate question that no cell-level screen can answer.If the search succeeds, the outcome is likely to be modest and specific: a defined combination that improves one cell type's function, delivered locally, for one age-associated disease. That is a smaller claim than [[epigenetic-reprogramming]] rhetoric usually makes, and it is also the version most likely to reach a patient. Whether such a therapy would generalize to the organism, which is what the [[geroscience-hypothesis]] requires, is a separate question that no cell-level screen can answer. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
94 lines are the same in both revisions, and 49 of them are not shown. Neither revision here is necessarily the current article — read NewLimit for the text this wiki stands behind today.